PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two abstracts have been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, IL, from March 31-April 4.
Abstract number 5241, entitled “Development of a single Listeria monocytogenes-based vaccine that targets two simultaneous antigens” by Dr. Anu Wallecha, et. al., Advaxis, will report on anti-tumor effects and antigen specific immune responses in mouse models generated by an Lm-LLO based immunotherapy consisting of two antigens, cHER2 and VEGFR2.
Abstract number 5243, entitled “Reductions in Hypoxia in the Tumor Microenvironment after Listeria monocytogenes-LLO based Immunotherapy” by Dr. Reshma Singh, et. al., Advaxis, will report on preclinical research demonstrating alterations in the oxygen supply in the interior of the tumor microenvironment after treatment with an Lm-LLO based immunotherapy containing a fusion protein directed to the hypoxia marker CA9.
Both posters will be presented on Wednesday, April 4, 2012 during the Drug Targets, Tumor Dormancy, and Microenvironment session from 8:00 am - 12:00 pm in McCormick Place West - Hall F, Poster Section 14.
“The posters that will be presented at AACR describe the exciting early results of a novel immunotherapy based on a new antigen and a bivalent immunotherapy technology that delivers two different antigen-adjuvant fusion proteins from a single bioengineered Listeria, representing the next generation of Advaxis immunotherapies,” commented Dr. John Rothman, Executive Vice President of Science and Operations at Advaxis.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
Advaxis’ lead construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (CRUK study) with over 190 patients receiving over 450 doses to date. Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn
Forward-Looking Statements
This news release contains forward-looking statements, including, but not limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2011, which is available at www.sec.gov. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.